Imiglucerase
Orphan Drug Cold Chain RequiredFDA Approved
Description
Imiglucerase is a recombinant DNA-derived form of the human enzyme acid beta-glucosidase. It is used as enzyme replacement therapy for patients with Gaucher disease.
Indications & Therapeutic Use
Gaucher's disease type I, Gaucher's disease type III
Linked Diseases:
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| Registered | — | 5 days | Commercially available | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Imiglucerase
| Generic Name | Imiglucerase |
| Brands | 1 brand available |
| Active Ingredient | Imiglucerase |
| Drug Class | Gaucher's disease type I |
| Manufacturer | Sanofi Genzyme |
| Dosage Forms | IV infusion, 200 units/vial, 400 units/vial |
| Medical Code | A16AB02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes